A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in patients with Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2020
This article has no abstract
Epistemonikos ID: e73b713d343f61a713a5563c9c1d4eba16d40630
First added on: Dec 15, 2020